Vetoquinol SA
PAR:VETO
Vetoquinol SA
Research & Development
Vetoquinol SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vetoquinol SA
PAR:VETO
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sanofi SA
PAR:SAN
|
Research & Development
-€7.8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
|
Ipsen SA
PAR:IPN
|
Research & Development
-€754m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-15%
|
|
|
Virbac SA
PAR:VIRP
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boiron SA
PAR:BOI
|
Research & Development
-€5.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-3%
|
|
|
Medincell SA
PAR:MEDCL
|
Research & Development
-€24.9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Vetoquinol SA
Glance View
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
